^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
DRUG CLASS:

CDH17-targeted antibody-drug conjugate

Associations
Trials
17d
A Study of LM-350 in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
P1/2, N=80, Recruiting, LaNova Medicines Limited | Not yet recruiting --> Recruiting | N=55 --> 80
Enrollment open • Enrollment change • First-in-human
28d
First-in-human Study of 7MW4911 in GI Cancer (clinicaltrials.gov)
P1/2, N=200, Recruiting, Mabwell (Shanghai) Bioscience Co., Ltd. | Not yet recruiting --> Recruiting
Enrollment open • First-in-human
2ms
New P1/2 trial
|
Avastin (bevacizumab) • 5-fluorouracil • capecitabine • oxaliplatin • leucovorin calcium
2ms
A Study of MRG007 (ARR-217) in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1, N=405, Recruiting, Lepu Biopharma Co., Ltd. | Phase classification: P1/2 --> P1
Phase classification
2ms
A Phase 1 Study of HDM2017 in Advanced Solid Tumors (clinicaltrials.gov)
P1, N=96, Recruiting, Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
New P1 trial
2ms
New P1 trial • First-in-human
2ms
First-in-human Study of 7MW4911 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=200, Recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
New P1/2 trial • First-in-human
3ms
Study of CM518D1 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=434, Recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Recruiting
Enrollment open
4ms
First-in-human Study of 7MW4911 in GI Cancer (clinicaltrials.gov)
P1/2, N=200, Not yet recruiting, Mabwell (Shanghai) Bioscience Co., Ltd.
New P1/2 trial • First-in-human
4ms
First in Human Study of TORL-3-600 in Participants With Advanced Cancer (clinicaltrials.gov)
P1, N=70, Active, not recruiting, TORL Biotherapeutics, LLC | Recruiting --> Active, not recruiting | Trial primary completion date: Sep 2025 --> Jun 2026
Enrollment closed • Trial primary completion date • First-in-human
6ms
A Study of LM-350 in Subjects With Advanced Solid Tumours (clinicaltrials.gov)
P1/2, N=55, Not yet recruiting, LaNova Medicines Limited
New P1/2 trial
6ms
A Study of MRG007 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
P1/2, N=336, Recruiting, Shanghai Miracogen Inc. | Not yet recruiting --> Recruiting
Enrollment open